Literature DB >> 26771313

Estimates of prostate cancer burden in Italy.

R Capocaccia1, R Foschi2, A Zucchetto3, R Valdagni4, N Nicolai5, M Maffezzini5, G Gatta2.   

Abstract

Age-standardized incidence rates of prostate cancer (PC) sharply increased during the period 1990-2005 in Italian areas covered by cancer registries, while corresponding mortality rates remained nearly constant. The latest observations have reported on a reversal of the incidence trend with decreasing values after 2005. We provided incidence, mortality, and prevalence estimates at national and geographical area levels, together with time projections up to the year 2020. We applied the MIAMOD method, using as input national mortality data for the years 1970-2010 and population-based survival data for the period of diagnosis (1985-2002). We assumed relative survival of prostate cancer remained constant after the year of diagnosis (2005). The age-standardized incidence rates of PC were estimated to increase during the period 1984-2005, from 31 per 100,000 in 1984 to 93 per 100,000 in 2005. From 2005 onwards, the estimated rates declined to 71 in 2015 and to 62 in 2020. Age-standardized mortality rates slightly increased from 1970 up to about 19 per 100,000 in 1999 and then started to decrease with an estimated reduction of about 2.3% per year. Mortality projections indicated a continuing reduction, with a predicted age-standardized rate of about 12 per 100,000 in 2020. Prevalence was estimated to continuously increase up to a crude prevalence value of 1.2% in the year 2020. The results indicate that the epidemic peak of PC was reached around the year 2005 followed by declining incidence rates, while a substantial decrease in mortality, starting during the early 2000s, is expected to continue during the 2010s.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Incidence; Mortality; Prevalence; Prostate cancer; Time trends

Mesh:

Year:  2015        PMID: 26771313     DOI: 10.1016/j.canep.2015.12.004

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  3 in total

1.  Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience.

Authors:  Vincenzo Mirone; Ciro Imbimbo; Davide Arcaniolo; Marco Franco; Roberto La Rocca; Luca Venturino; Lorenzo Spirito; Massimiliano Creta; Paolo Verze
Journal:  World J Urol       Date:  2017-08-05       Impact factor: 4.226

Review 2.  Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2017 Sep-Oct

Review 3.  Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Authors:  Vincenzo Quagliariello; Sabrina Rossetti; Carla Cavaliere; Rossella Di Palo; Elvira Lamantia; Luigi Castaldo; Flavia Nocerino; Gianluca Ametrano; Francesca Cappuccio; Gabriella Malzone; Micaela Montanari; Daniela Vanacore; Francesco Jacopo Romano; Raffaele Piscitelli; Gelsomina Iovane; Maria Filomena Pepe; Massimiliano Berretta; Carmine D'Aniello; Sisto Perdonà; Paolo Muto; Gerardo Botti; Gennaro Ciliberto; Bianca Maria Veneziani; Francesco De Falco; Piera Maiolino; Michele Caraglia; Maurizio Montella; Rosario Vincenzo Iaffaioli; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.